Proton Pump Inhibitor Therapy for Suspected GERD-Related Chronic Laryngitis: A Meta-Analysis of Randomized Controlled Trials

Authors: Qadeer, Mohammed A.¹; Phillips, Christopher O.; Lopez, A. Rocio²; Steward, David L.³; Noordzij, J. Pieter⁴; Wo, John M.⁵; Suurna, Maria³; Havas, Thomas⁶; Howden, Colin W.⁷; Vaezi, Michael F.⁸

Source: The American Journal of Gastroenterology, Volume 101, Number 11, November 2006 , pp. 2646-2654(9)

Publisher: Blackwell Publishing

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

OBJECTIVE: The role of proton pump inhibitors (PPIs) in suspected GERD-related chronic laryngitis (CL) is controversial. Hence, we performed a meta-analysis of the existing randomized controlled trials (RCTs) to evaluate the efficacy of PPIs in this disorder.

METHODS: Data extracted from MEDLINE (1966 to August 2005), Cochrane Controlled Trials Register (1997 to August 2005), EMBASE (1980 to August 2005), ClinicalTrials.gov website, and meetings presentations (1999-2005). Published and unpublished randomized placebo-controlled trials of PPIs in suspected GERD-related CL were selected by consensus. Random effects model was utilized with standard approaches to quality assessment, sensitivity analysis, and an exploration of heterogeneity and publication bias. The primary outcome measure was defined as the proportion of patients with ≥50% reduction in self-reported laryngeal symptoms.

RESULTS: Pooled data from 8 studies (N = 344, PPI 195, placebo 149; mean age 51 yr; males 55%; study duration 8-16 wk) were analyzed. No significant quantitative heterogeneity was found among the studies (χ²= 11.22, P= 0.13). Overall, PPI therapy resulted in a nonsignificant symptom reduction compared to placebo (relative risk 1.28, 95% confidence interval 0.94-1.74). No clinical predictors of PPI response were identified on meta-regression analysis done at study level.

CONCLUSIONS: PPI therapy may offer a modest, but nonsignificant, clinical benefit over placebo in suspected GERD-related CL. Validated diagnostic guidelines may facilitate the recognition of those patients most likely to respond favorably to PPI treatment.

(Am J Gastroenterol 2006;101:2646-2654)

Document Type: Research article

DOI: 10.1111/j.1572-0241.2006.00844.x

Affiliations: 1: Department of Gastroenterology and Hepatology 2: Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio 3: Department of Otolaryngology, University of Cincinnati, Cincinnati, Ohio 4: Department of Otolaryngology, Vanderbilt University, Nashville, Tennessee 5: Department of Gastroenterology, University of Louisville, Louisville, Kentucky 6: Department of Otolaryngology Head and Neck Surgery, University of New South Wales, Sydney, Australia 7: Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 8: Department of Gastroenterology, Vanderbilt University, Nashville, Tennessee

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax Refund Policy

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.